KALA BIO (NASDAQ:KALA – Get Free Report) announced its earnings results on Tuesday. The company reported ($1.93) EPS for the quarter, beating the consensus estimate of ($2.43) by $0.50, Zacks reports.
KALA BIO Trading Down 2.7 %
Shares of NASDAQ:KALA opened at $6.76 on Friday. KALA BIO has a 52-week low of $4.21 and a 52-week high of $10.97. The business’s 50 day simple moving average is $6.00 and its two-hundred day simple moving average is $6.29. The company has a current ratio of 2.15, a quick ratio of 3.07 and a debt-to-equity ratio of 3.18.
Wall Street Analysts Forecast Growth
Separately, Oppenheimer reiterated an “outperform” rating and issued a $15.00 price objective on shares of KALA BIO in a research note on Monday, August 19th.
KALA BIO Company Profile
KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.
Read More
- Five stocks we like better than KALA BIO
- 3 Warren Buffett Stocks to Buy Now
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
- What is Short Interest? How to Use It
- Q3 Earnings Indicate On Holdings May Outperform Lululemon in 2024
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Cisco Systems Long-Term AI Play Turns a Corner: New Highs Likely
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
